SE‑Cluster

Search

Search markets, companies, evidence, and pages

Machine Verified Markets
Market strategy briefQ2 2026Next refresh: mid-Nov 2026

Higher Spend Concentration + Slower posture

Life Sciences Tools, Diagnostics & MedTech

Higher Spend Concentration + Slower · $366.1B disclosed spend · led by Bolt On plays · activity cooling across 155 public buyers.

Priority buyers pair regulatory know-how and commercial channels with repeat acquisitions that fill product, testing, or workflow gaps.

Bolt On dominantSpend HHI 716Cooling -27

Disclosed acquisition spend is above the atlas median HHI (576), while recent activity is flat or cooling.

Public buyers

155

70 core (10+)

Recorded buys

1,334

182 last 3 yrs

Disclosed spend

$366.1B

$68.3B recent

Matched issuers

289

4 segments

Strategy fingerprint

How this market gets bought

Spend-weighted strategy mix from public buyers' 10-K language. Each archetype shows the buyers who lead it.

Bolt 21%
Geo 20%
Horiz 19%
Platform 16%
Tech 13%
Tuck InBolt OnPlatformGeographic ExpansionHorizontal ConsolidationVertical IntegrationTechnology AcquisitionTalent Acquisition

Tuck In

8% mix

Small additive deals folded directly into the existing business.

Bolt On

21% mix

Mid-sized acquisitions extending the existing product or service core.

“The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforces.”

Thermo Fisher Scientific Inc. (TMO) · FY2023

Platform

16% mix

Foundational deals establishing a new platform or business line.

“The acquisition is expected to accelerate access and adoption of GRAIL’s blood test”

Illumina, Inc. (ILMN) · FY2022

Geographic Expansion

20% mix

Buying density or new geographies to extend the footprint.

“During 2025, the Company advanced its international strategy through the acquisition of a minority stake in SYNLAB, a leader in medical diagnostic services and specialty testing in Europe.”

Labcorp Holdings Inc. (LH) · FY2025

Horizontal Consolidation

19% mix

Acquiring direct competitors to consolidate the market.

“Market consolidation of large customers globally through mergers or acquisitions resulting in a larger proportion or concentration of our business being derived from fewer customers.”

The Cooper Companies, Inc. (COO) · FY2025

Vertical Integration

1% mix

Adding upstream or downstream capability inside the value chain.

Technology Acquisition

13% mix

Buying products, IP, or engineering depth for capability gain.

“We believe that our products and solutions compete primarily on their ability to deliver both differentiated clinical and economic outcomes for our customers by enabling physicians to perform diagnostic and therapeutic procedures safely and effectively often in a less-invasive and cost effective manner.”

Boston Scientific Corp. (BSX) · FY2025

Talent Acquisition

3% mix

Acquisitions led by team or human-capital rationale.

Buyer landscape

Disclosed buyer scale by annual spend

Each bubble is a top public buyer with disclosed acquisition spend. X = average disclosed spend per active year. Y = total disclosed spend. Midlines are buyer medians. Color = dominant strategy archetype.

Below-median disclosed spend per active year, above-median total disclosed spend.Lower Annual Spend / Higher Total SpendAbove-median disclosed spend per active year, above-median total disclosed spend.Higher Annual Spend / Higher Total SpendBelow-median disclosed spend per active year, below-median total disclosed spend.Lower Annual Spend / Lower Total SpendAbove-median disclosed spend per active year, below-median total disclosed spend.Higher Annual Spend / Lower Total Spend$100M$1B$1B$10Bmedian annual $339Mmedian total $4.8BAvg disclosed acquisition spend per active year (log) →Total disclosed spend (log)BDXBecton, Dickinson and Company (BDX) Bolt On $60.3B total · $4B / active year 15 active years · 16 buys reportedTMOThermo Fisher Scientific Inc. (TMO) Bolt On $52.9B total · $3.5B / active year 15 active years · 20 buys reportedDHRDanaher Corp. (DHR) Bolt On $34.9B total · $3.9B / active year 9 active years · 149 buys reportedBSXBoston Scientific Corp. (BSX) Technology Acquisition $22.1B total · $1.2B / active year 18 active years · 52 buys reportedMDTMedtronic plc (MDT) Bolt On $18.3B total · $1.8B / active year 10 active years · 6 buys reportedTFXTeleflex Incorporated (TFX) Bolt On $14.5B total · $850M / active year 17 active years · 42 buys reportedLHLabcorp Holdings Inc. (LH) Geographic Expansion $13.6B total · $757M / active year 18 active years · 7 buys reportedBAXBaxter International Inc. (BAX) Bolt On $11.4B total · $948M / active year 12 active years · 11 buys reportedRVTYRevvity, Inc. (RVTY) Horizontal Consolidation $8.4B total · $562M / active year 15 active years · 58 buys reportedIQVIqvia Holdings Inc. (IQV) Bolt On $8.4B total · $843M / active year 10 active years · 3 buys reportedABTAbbott Laboratories (ABT) Geographic Expansion $8B total · $1.1B / active year 7 active years · 13 buys reportedICLRICON plc (ICLR) Geographic Expansion $7B total · $467M / active year 15 active years · 22 buys reportedAAgilent Technologies, Inc. (A) Geographic Expansion $6.6B total · $442M / active year 15 active years · 39 buys reportedPHGKoninklijke Philips NV (PHG) Bolt On $6.5B total · $809M / active year 8 active years · 16 buys reportedIARTIntegra Lifesciences Holdings Corp. (IART) Bolt On $6.1B total · $382M / active year 16 active years · 47 buys reportedSYKStryker Corp. (SYK) Geographic Expansion $5.7B total · $333M / active year 17 active years · 16 buys reportedCRLCharles River Laboratories International, Inc. (CRL) Bolt On $5.3B total · $405M / active year 13 active years · 23 buys reportedCOOThe Cooper Companies, Inc. (COO) Horizontal Consolidation $5.1B total · $302M / active year 17 active years · 11 buys reportedRMDResMed Inc. (RMD) Mixed strategy $4.4B total · $260M / active year 17 active yearsNEOGNeogen Corporation (NEOG) Bolt On $3.6B total · $224M / active year 16 active years · 28 buys reportedILMNIllumina, Inc. (ILMN) Platform $3.4B total · $279M / active year 12 active years · 9 buys reportedLMATLemaitre Vascular, Inc. (LMAT) Bolt On $3B total · $197M / active year 15 active years · 16 buys reportedQGENQiagen N.v. (QGEN) Bolt On $2.5B total · $139M / active year 18 active years · 25 buys reportedWATWaters Corporation (WAT) Mixed strategy $2.5B total · $178M / active year 14 active yearsBRKRBruker Corporation (BRKR) Bolt On $2.5B total · $164M / active year 15 active years · 51 buys reportedSMTISanara Medtech Inc. (SMTI) Technology Acquisition $2.2B total · $373M / active year 6 active years · 4 buys reportedATRAptarGroup, Inc (ATR) Geographic Expansion $1.6B total · $102M / active year 16 active years · 19 buys reportedITGRInteger Holdings Corporation (ITGR) Bolt On $1.6B total · $123M / active year 13 active years · 16 buys reportedEWEdwards Lifesciences Corporation (EW) Technology Acquisition $1.5B total · $136M / active year 11 active years · 10 buys reportedRGENRepligen Corp. (RGEN) Bolt On $1.4B total · $110M / active year 13 active years · 16 buys reportedNVSTEnvista Holdings Corporation (NVST) Bolt On $1.4B total · $346M / active year 4 active years · 4 buys reportedCNMDConmed Corporation (CNMD) Bolt On $1.4B total · $99M / active year 14 active years · 10 buys reportedBIOBio-Rad Laboratories, Inc. (BIO) Mixed strategy $1.2B total · $88M / active year 14 active years · 11 buys reportedMMSIMerit Medical Systems Inc. (MMSI) Geographic Expansion $996M total · $52M / active year 19 active years · 35 buys reportedGMEDGlobus Medical, Inc. (GMED) Technology Acquisition $934M total · $67M / active year 14 active years · 15 buys reportedHAEHaemonetics Corporation (HAE) Technology Acquisition $844M total · $77M / active year 11 active years · 8 buys reported
BuyerDominant playDisclosed spendSpend / yrBuys3-yr spend trend
Becton, Dickinson and CompanyBDXBolt On
$60.3B
$4B16

Accelerating

+253%

Thermo Fisher Scientific Inc.TMOBolt On
$52.9B
$3.5B20

Cooling

-44%

Danaher Corp.DHRBolt On
$34.9B
$3.9B149

Paused

$21.6B prior

Boston Scientific Corp.BSXTechnology Acquisition
$22.1B
$1.2B52

Steady

-2%

Medtronic plcMDTBolt On
$18.3B
$1.8B6

New cycle

$2.2B recent

Teleflex IncorporatedTFXBolt On
$14.5B
$850M42

Cooling

-72%

Labcorp Holdings Inc.LHGeographic Expansion
$13.6B
$757M7

Steady

+9%

Baxter International Inc.BAXBolt On
$11.4B
$948M11

Winding down

$11.1B → $6M

Revvity, Inc.RVTYHorizontal Consolidation
$8.4B
$562M58

Paused

$4.4B prior

Iqvia Holdings Inc.IQVBolt On
$8.4B
$843M3

Steady

+11%

Abbott LaboratoriesABTGeographic Expansion
$8B
$1.1B13

New cycle

$1.8B recent

ICON plcICLRGeographic Expansion
$7B
$467M22

Winding down

$5.9B → $156M

Playbook theatre

The language of consolidation, by archetype

Direct sentences from public buyers' 10-K filings, grouped by the strategy they describe.

“The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforces.”

Thermo Fisher Scientific Inc.TMOFY2023

“we may fail to identify attractive opportunities to consolidate with larger or smaller companies to expand our business”

Teleflex IncorporatedTFXFY2025

“Finally, Core Spine net sales also benefited from the acquisition of Titan Spine in the first quarter of fiscal year 2020.”

Medtronic plcMDTFY2020

“ongoing efforts to streamline our global operations and reduce overcapacity to adapt to changing market conditions and integrate acquisitions”

Iqvia Holdings Inc.IQVFY2022

“Although no single company competes with us in all of our businesses, we face substantial competition in each of our segments from international and domestic healthcare, medical products and pharmaceutical companies and providers of all sizes, and these competitors often differ across our businesses.”

Baxter International Inc.BAXFY2025

“growth through acquisitions”

Integra Lifesciences Holdings Corp.IARTFY2024

Submarkets

Where the cadence lives

Activity intensity, lead buyers, and footprint per segment within this market.

Diagnostics & Research Tools

514

Diagnostics, clinical testing, research tools, lab automation, and assay/workflow platforms.

Buyers

40

Core

23

Spend

$160.8B

2006–2025 · last year 13

Instruments, Supplies & Equipment

349

Medical instruments, supplies, equipment, consumables, and installed-base product portfolios.

Buyers

42

Core

23

Spend

$119.6B

2006–2025 · last year 20

Medical Devices & Implants

518

Medical devices, implants, surgical tools, procedure-specific products, and regulated device platforms.

Buyers

69

Core

24

Spend

$85.4B

2006–2025 · last year 53

Lab Services & Bioprocessing

9

Life-science services, bioprocessing tools, contract research support, and laboratory service platforms.

Buyers

4

Core

0

Spend

$216M

2006–2025 · last year 0

Accelerators

Recent 3-yr cadence above prior

8

Coolers

Recent 3-yr cadence below prior

8

Trajectory

20 years of cadence and spend

Annual recorded buys and disclosed spend across the matched buyer set.

0531052006: 78 buys · $6.2B spend · 22 buyers2007: 37 buys · $11.6B spend · 19 buyers2008: 73 buys · $3.8B spend · 28 buyers2009: 40 buys · $3.9B spend · 23 buyers2010: 37 buys · $4.2B spend · 26 buyers2011: 80 buys · $12.2B spend · 37 buyers2012: 81 buys · $7.8B spend · 42 buyers2013: 50 buys · $4.9B spend · 27 buyers2014: 66 buys · $4B spend · 30 buyers2015: 66 buys · $31.3B spend · 32 buyers2016: 83 buys · $17.1B spend · 36 buyers2017: 83 buys · $20.5B spend · 31 buyers2018: 78 buys · $27.6B spend · 37 buyers2019: 66 buys · $35.3B spend · 36 buyers2020: 67 buys · $31.1B spend · 42 buyers2021: 105 buys · $62.9B spend · 46 buyers2022: 62 buys · $13.5B spend · 35 buyers2023: 47 buys · $21.4B spend · 36 buyers2024: 71 buys · $21.4B spend · 44 buyers2025: 64 buys · $25.5B spend · 44 buyers2006: 78 buys · $6.2B spend · 22 buyers2007: 37 buys · $11.6B spend · 19 buyers2008: 73 buys · $3.8B spend · 28 buyers2009: 40 buys · $3.9B spend · 23 buyers2010: 37 buys · $4.2B spend · 26 buyers2011: 80 buys · $12.2B spend · 37 buyers2012: 81 buys · $7.8B spend · 42 buyers2013: 50 buys · $4.9B spend · 27 buyers2014: 66 buys · $4B spend · 30 buyers2015: 66 buys · $31.3B spend · 32 buyers2016: 83 buys · $17.1B spend · 36 buyers2017: 83 buys · $20.5B spend · 31 buyers2018: 78 buys · $27.6B spend · 37 buyers2019: 66 buys · $35.3B spend · 36 buyers2020: 67 buys · $31.1B spend · 42 buyers2021: 105 buys · $62.9B spend · 46 buyers2022: 62 buys · $13.5B spend · 35 buyers2023: 47 buys · $21.4B spend · 36 buyers2024: 71 buys · $21.4B spend · 44 buyers2025: 64 buys · $25.5B spend · 44 buyers20062011201620212025
Recorded buysDisclosed spend (rescaled)